Twist Bioscience (NASDAQ:TWST) 주식

Twist Bioscience

Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to realize opportunities ahead rapidly. Geographically, it derives a majority of its revenue from the United States.

Cathie Wood-Led Ark Invest Dumps $7M Worth Of Palantir Stock Amid Searing Rally

Equities

News

Markets

ETFs

ACCD

ACHR

ADYEY

ARKG

ARKK

ARKQ

ARKX

EXAS

IRDM

RXRX

TWST

2025년 2월 28일 금요일 캐시 우드의 아크 인베스트가 몇 가지 주목할 만한 거래를 진행했다. 그중 가장 두드러진 것은 아처 에비에이션(NYSE:ACHR), 리커전 파마슈티컬스(NASDAQ:RXRX), 템퍼스AI(NASDAQ:TEM), 그리고 이리디움 커뮤니케이션스(NASDAQ:IRDM)의 주식을 매수한 것이다.

아크 인베스트: 템퍼스AI 및 아처 에비에이션 주식 매수, 트위스트 바이오사이언스는 매각

Cathie Wood's Flurry Of Trades: Offloads $31.5M in Tesla, Buys Amazon, AMD And Meta — Dumps Palantir, Trims Robinhood And Square Amid Bitcoin Rally

Tech

ARKF

ARKW

BEAM

IBTA

ROKU

금요일에 캐시 우드가 이끄는 아크 인베스트가 이리듐 커뮤니케이션스(NASDAQ:IRDM), 트위스트 바이오사이언스(NASDAQ:TWST), 페이저듀티(NYSE:PD), 빔 테라퓨틱스(NASDAQ:BEAM), 로쿠(NASDAQ:ROKU), 그리고 아이보타(NASDAQ:IBTA)와 같은 주식들에 대해 중요한 거래를 진행했다.

아크 인베스트의 금요일 거래, 이리듐과 트위스트 바이오사이언스를 매수, 로쿠를 매도

Ark Invest's Cathie Wood Joins Call For Strategic Bitcoin Reserve, Gives Thumbs Up To Cynthia Lummis' Plan

ILMN

PATH

PLTR

캐시 우드가 이끄는 아크 인베스트가 월요일(10일)에 상당한 규모의 거래를 했다. 가장 눈에 띄는 것은 팔란티어 테크놀로지스(NASDAQ:PLTR) 주식의 매각이었는데, 팔란티어 주가가 인상적인 재무 실적 이후 계속 상승세를 이어가고 있었기 때문이다.

아크 인베스트, 팔란티어 주식 1,600만 달러 상당 추가 매각

Twist Bioscience Corporation - Common Stock

Twist Bioscience Corp

Ki Young Ju, Founder and CEO of on-chain analytics platform CryptoQuant, says he's open to conceding a major forecast error, if Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44380265/bitcoin-is-past-the-bull-cycle-peak-top-analyst-warns">breaks above $100,000.</a>
What Happened: In a <a href="https://x.com/ki_young_ju/status/1915001569638256692">post </a>on X (formerly Twitter), Ju acknowledged that Bitcoin is now trading 10% higher than when he recently declared the bull cycle to be over.
Despite the move, he remains cautious, stating, "If it breaks above $100K, I'll gladly admit I was wrong."
Ju's recent comments on X follow his earlier analysis, which flagged a potential market top based on historical on-chain data.
CryptoQuant's proprietary PnL Index chart, which tracks Bitcoin's price against on-chain profitability metrics over a decade, recently issued a sell signal similar to those in 2013, 2017, and 2021, each preceding significant corrections or consolidation. 
"We are likely past the bull cycle peak," Ju had warned, anticipating sideways or bearish movement for six to twelve months. However, Bitcoin's price has since risen 10% above his initial call, despite a recent 10% drop.
The comments come amid a volatile week in crypto markets. 
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44987075/why-bitcoin-reclaiming-92900-could-be-a-pivotal-moment-glassnode">Why Bitcoin Reclaiming $92,900 Could Be A Pivotal Moment: Glassnode</a>
Why It Matters: As of Thursday evening European time, Bitcoin is trading around $93,000, down about 1% on the day.
Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) is lower at $1,755, while XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>), BNB (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/bnb/usd">BNB</a>), and Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>) are showing modest declines or trading flat.
Ju emphasized that short-term market moves are increasingly driven by event-based reactions, referencing political developments—making them difficult to interpret with traditional on-chain cycle indicators. 
"My focus is on long-term supply and demand using on-chain data," he noted. "But in a market that reacts to every Trump comment, short-term price actions are much more event-driven."
He added that if Bitcoin reaches a new all-time high before Q4, he would be forced to reconsider prevailing cycle theories: "In that case, the permabulls were right. Up only."
Iliya Kalchev, an analyst at Nexo Dispatch, commented on broader market influences, stating, "Today's U.S. calendar includes initial jobless claims and existing home sales, key reads on labor market health and consumer confidence." 
He added that Friday's University of Michigan consumer sentiment index and Alphabet's earnings could further impact risk appetite amid trade policy uncertainty.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44986939/saros-to-deploy-dlmm-technology-on-solana-aiming-to-improve-defi-liquidity-and-reduce-systemic-risks">Saros To Deploy DLMM Technology On Solana, Aiming To Improve DeFi Liquidity And Reduce Systemic Risks</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BNB

$BTC

$ETH

$SOL

$XRP

If Bitcoin Breaks $100K, This CEO Will 'Gladly Admit' Being Wrong About A Bear Market

Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) stock ended 2024 on a high note with shares hitting all-time highs in December, helping boost the wealth of CEO Elon Musk. The start of 2025 has been anything but the same, <a href="https://www.benzinga.com/25/04/44963440/tesla-takedown-says-protests-are-working-hitting-ev-company-where-it-hurts-the-companys-bottom-line">with shares down</a> and Musk's wealth falling by more than $100 billion.
What Happened: Musk ended 2024 as the world's richest person <a href="https://www.benzinga.com/news/management/25/01/42771258/worlds-top-10-richest-people-gained-more-wealth-in-2024-than-costco-and-nikes-combined-valuation-how-elon-musk-warren-buffett-and-others-fared">worth an estimated </a>$432 billion. The Tesla CEO added $203 billion to his wealth in 2024 and was the first person in the world to hit the $400 billion milestone.
As <a href="https://www.benzinga.com/general/sports/24/12/42521401/elon-musk-is-so-rich-he-could-buy-every-mlb-nba-nfl-nhl-team-and-still-have-cash-left-over">Benzinga previously shared, </a>Musk's wealth in 2024 was so high that he was worth more than every MLB, NBA, NFL and NHL team combined.
Fast forward to April 2025 and Musk is now worth $310 billion, according to <a href="https://www.bloomberg.com/billionaires/">Bloomberg</a>. This represents a decline of $122 billion from where Musk began the year.
With a wealth of $310 billion, Musk is still significantly ahead of the other billionaires of the world.
Amazon founder Jeff Bezos ranks second with a wealth of $202 billion, losing $36.8 billion in wealth in 2025.
So what's crazy is that Musk is now worth more than the following figures combined:
<ul>
<li>Jeff Bezos (Amazon founder): $202 billion</li>
<li>Jensen Huang (NVIDIA co-founder): $90 billion</li>
<li>Mark Cuban (entrepreneur, NBA owner): $7.55 billion</li>
<li>Total: $299.55 billion</li>
</ul>
That's right, Musk is worth more than the three billionaires combined. In fact, you could add in Palantir CEO Alex Karp, who is worth $9.35 billion and still be under Musk's current wealth.
Are you buying when the CEOs of the Magnificent 7 are selling?
<ul>
<li>Stay in the know with our Insider Trades page — <a href="https://www.benzinga.com/sec/insider-trades/">see when leaders like Mark Zuckerberg, Elon Musk, and Jensen Huang are offloading their own shares.</a></li>
</ul>
Why It's Important: Musk's wealth drop highlights the downfall of Tesla stock year-to-date in 2025. Shares hit new all-time highs in December and soared after Donald Trump won the 2024 presidential election.
Early in 2025, Tesla stock fell after Trump took office and Musk's role in the White House with the Department of Government Efficiency led to calls for boycotts against Tesla and protests at dealerships.
Tesla lost brand value and sales began slipping in Europe and other regions.
Tesla stock is now down 32.6% year-to-date in 2025. Musk remains a large shareholder in Tesla and the EV stock makes up a large portion of his wealth, along with stakes in X, SpaceX, xAI and other companies.
In 2021, Musk <a href="https://www.benzinga.com/news/23/01/30362822/elon-musk-wins-a-guinness-world-record-but-he-likely-wont-be-celebrating">set a Guinness World Record </a>for the largest one-year drop in his wealth, losing between $180 billion and $200 billion. The billionaire is currently on pace to break that record, but a turnaround of Tesla stock with several catalysts coming later this year could help keep Musk from breaking his own record.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/25/03/44479393/warren-buffett-top-wealth-gainer-elon-musk-top-wealth-loser-in-2025-heres-how-much-billionaires-have-added-lost">Warren Buffett Top Wealth Gainer, Elon Musk Top Wealth Loser In 2025: Here&#8217;s How Much Billionaires Have Added, Lost</a></li>
</ul>
Image created using photos from Shutterstock.

Education

Management

TSLA

Elon Musk Is $122 Billion Poorer In 2025, And Still Richer Than Bezos, Huang, Cuban Combined

WIIM

MaxLinear shares are trading lower. The company reported Q1 financial results.

Benchmark analyst David Williams reiterates MaxLinear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MXL#NASDAQ">MXL</a>) with a Buy and maintains $20 price target.

Price Target

Reiteration

Analyst Ratings

Benchmark Reiterates Buy on MaxLinear, Maintains $20 Price Target

Finland-based Nokia Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOK#NYSE">NOK</a>) stock is trading lower on Thursday after its first-quarter FY25 earnings.
The telecommunications <a target="_blank" href="https://www.nokia.com/about-us/news/releases/2025/04/24/nokia-corporation-interim-report-for-q1-2025/" rel="noreferrer noopener">major opened 2025 with mixed financial results,</a> with net sales sliding 3% year-over-year on a constant currency and portfolio-adjusted basis.
The Network Infrastructure segment posted an 11% rise, and Cloud and Network Services increased by 8%. Mobile Networks also edged up 2%, offering some resilience amid broader headwinds stemming from a tough comparison with the prior year's performance in Nokia Technologies.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/25/04/44961625/fda-targets-synthetic-food-dyes-in-sweeping-nutrition-overhaul" rel="noreferrer noopener">Automakers Are Struggling With Tariffs And EV Competition, Say Analysts</a>
The company reported a huge drop in gross margins, down 820 basis points year-over-year to 42.3% on a comparable basis, driven by reduced revenues from Nokia Technologies and a 120 million euros ($136.57 million) charge related to contract settlements in Mobile Networks.
Operating margins also shrank to 3.6% on a comparable basis. Diluted earnings per share for the first-quarter came in at 0.03 euros ($0.034).
"Regarding the tariff situation, there could be some short-term disruption. We will continue to utilize the flexibility of our global manufacturing network to minimize impact of the evolving tariff landscape. Based on what we see today, we currently expect a 20 to 30 million euros impact to our comparable operating profit in the second quarter from the current tariffs," said President and CEO Justin Hotard.
Nokia reaffirmed its full-year outlook, maintaining a projected operating profit between 1.9 billion euros and 2.4 billion euros and a free cash flow conversion rate of 50% to 80%.
In other news, Nokia has deepened its collaboration with T-Mobile US Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) through a <a target="_blank" href="https://www.nokia.com/about-us/news/releases/2025/04/24/nokia-lands-strategic-5g-ran-deal-with-t-mobile-us-to-enhance-nationwide-connectivity/" rel="noreferrer noopener">new agreement focused on enhancing</a> and extending 5G services nationwide.
Nokia will provide a range of advanced solutions from its AirScale Radio Access Network lineup to elevate the Un-carrier's connectivity reach and performance.
The partnership involves rolling out Nokia's Habrok Massive MIMO antennas and Levante baseband platforms, both driven by the company's energy-efficient ReefShark chip technology.
These systems are designed to boost the network's performance, stability, and data speeds while minimizing power usage. Additionally, AI-driven solutions such as MantaRay SON and AutoPilot will help streamline and enhance T-Mobile's network's operational efficiency.
T-Mobile's network now covers over 332 million people and two million square miles, and Nokia has been its trusted RAN partner for many years.
Price Action: NOK shares traded lower by 8.29% at $4.87 at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/25/04/44991419/nvidia-powers-next-gen-adaptive-digital-ai-agents-for-cisco-nasdaq-and-meta" target="_blank" rel="noreferrer noopener">Nvidia Powers Next-Gen Adaptive Digital AI Agents For Cisco, Nasdaq, And Meta</a></li>
</ul>
Photo via Shutterstock

Earnings

Guidance

Movers

General

TMUS

Why Is Finnish Telecom Giant Nokia Stock Plunging Thursday?

Nano Nuclear Energy shares are trading higher after the company announced it, along with the University of Illinois, received a Nuclear Regulatory Commission fuel qualification methodology approval for its KRONOS MMR energy system.

<a href="https://www.bloomberg.com/news/articles/2025-04-24/authentic-brands-group-weighs-rival-bid-for-guess">https://www.bloomberg.com/news/articles/2025-04-24/authentic-brands-group-weighs-rival-bid-for-guess</a>

'Authentic Brands Group Weighs Rival Bid For Guess?'- Bloomberg

Natural gas futures extended their relentless slide into a tenth consecutive session Thursday, marking the worst losing streak since October 2019, yet one veteran market strategist sees a sharp turnaround ahead <a href="https://www.benzinga.com/topic/donald-trump">if trade tensions ease.</a>
In a note shared Thursday, Ed Yardeni, president of Yardeni Research, said investors may be underestimating the underlying strength of U.S. natural gas demand, particularly from utilities and exporters of liquefied natural gas. 
&#8220;If tariffs subside, natural gas prices stand to bounce sharply," Yardeni said. 
<h1 class="wp-block-heading">Henry Hub Prices Touch 6-Month Lows Amid Tariff Uncertainty</h1>
The front-month Henry Hub natural gas contract — as broadly tracked by the United States Natural Gas Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNG#NYSE">UNG</a>) —&nbsp;traded at $2.90 per million British thermal units on Thursday, its lowest level in six months.
Prices earlier this week broke below the 200-day moving average, a technical occurrence unseen since September 2024, deepening the bearish sentiment gripping the market.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="528" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24141856/NG1_2025-04-24_20-18-44_31529-1024x528.png" alt="" class="wp-image-887310" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24141856/NG1_2025-04-24_20-18-44_31529-1024x528.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24141856/NG1_2025-04-24_20-18-44_31529-300x155.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24141856/NG1_2025-04-24_20-18-44_31529-768x396.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24141856/NG1_2025-04-24_20-18-44_31529-1536x792.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24141856/NG1_2025-04-24_20-18-44_31529.png 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
The ongoing rout comes in the wake of escalating trade tensions, including China&#8217;s retaliatory 49% tariff on U.S. liquefied natural gas imports, first introduced at 15% on Feb. 10. 
The tit-for-tat response to tariffs from the Trump administration has shaken global demand forecasts and altered trade flows, analysts said.
Chinese imports of U.S. LNG have plummeted to zero in recent months, according to shipping data cited by <a href="https://www.nytimes.com/2025/04/18/business/china-us-lng-trump-tariffs.html#:~:text=use%20in%20China.-,L.N.G.,to%20buy%20inexpensive%20Russian%20gas.">The New York Times. </a>
<h1 class="wp-block-heading">Supply Grows, But So Does Demand</h1>
Despite falling prices, U.S. production remains on an upward trajectory. Since 2022, output has increased by 1.5 trillion cubic feet, while consumption grew by 1.0 trillion and exports rose 0.8 trillion. 
Yardeni said this dynamic has left inventories thin, with U.S. natural gas stocks about 10% below the five-year average for this time of year.
&#8220;U.S. production of natural gas has increased nicely in recent years, but U.S. consumption and exports of the fuel have grown even faster," he said.
Since 2022, U.S. production has grown by 1.5 trillion cubic feet, while domestic consumption rose by one trillion and exports jumped by 0.8 trillion cubic feet.
The tight balance has drawn down inventories, leaving natural gas stocks about 10% below their five-year average for this time of year.
Data from the Energy Information Administration supports his view. U.S. consumption is projected to rise 1.8% in 2025 to 92 billion cubic feet per day, while LNG exports are forecast to jump 19% to 14.2 billion cubic feet per day.
While the short-term outlook for natural gas prices remains clouded by tariffs and geopolitical tensions, tight inventories and robust global demand suggest the current slump may not last.
Read Now: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44984872/gillette-parent-procter-gamble-slides-on-q3-sales-decline-lowered-outlook">Gillette And Tide Maker Procter &amp; Gamble Feels The Heat From Commodity And Forex Costs, Cuts Profit Outlook</a></li>
</ul>
Photo: <a href="https://www.shutterstock.com/g/sdf_qwe">sdf_qwe</a> via Shutterstock

Commodities

Natural Gas Hits 10-Day Losing Streak: Why Ed Yardeni Thinks 'Prices Stand To Bounce Sharply' From Here

RZLV

Rezolve AI shares are trading higher after the company announced it has passed $50 billion in gross merchandise value in 2025.

Needham analyst David Saxon reiterates Bausch &amp; Lomb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLCO#NYSE">BLCO</a>) from Hold to Hold.

BLCO

Needham Reiterates Hold on Bausch & Lombto Hold

Jones Trading analyst Jason Weaver reiterates PennyMac Mortgage IT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PMT#NYSE">PMT</a>) from Hold to Hold.

Jones Trading Reiterates Hold on PennyMac Mortgage ITto Hold

AAOI

AKAM

ANET

CALX

COHR

DELL

FLEX

KEYS

LITE

MRIN

NTAP

NVTS

OKTA

PSTG

SNOW

TWLO

ZBRA

Shares of companies in the broader tech sector are trading higher amid overall market strength due to March's strong durable goods orders economic data, and President Trump's announcement that he met with China earlier today. Also, the industry may be moving up ahead of Alphabet's earnings report scheduled for after market close.

VTMX

Vesta shares are trading higher after the company reported a Q1 FFO beat.

Jones Trading analyst Jason Weaver reiterates ARMOUR Residential REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARR#NYSE">ARR</a>) from Hold to Hold.

Jones Trading Reiterates Hold on ARMOUR Residential REITto Hold

ALLY

ARES

Bakkt Holdings, Inc. Class A Common Stock

BKKT

COIN

FUTU

HOOD

HUIZ

IBKR

INTR

LPRO

SHF Holdings, Inc. - Class A Common Stock

SHFS

SOFI

STEP

TREE

TROW

UPST

Shares of companies within the broader financial sector are trading higher amid overall market strength due to March's strong durable goods orders economic data, and President Trump's announcement that he met with China earlier today.

Edwards Lifesciences&#8216; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) shares are trading higher Thursday after the company reported first-quarter 2025 sales of $1.41 billion.
That&#8217;s almost in line with the <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus of $1.40 billion</a> and the management guidance of $1.35 billion—$1.43 billion, up 6.2% year-over-year or <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">7.9% on an adjusted basis</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44652075/us-tariffs-spare-drugmakers-but-threaten-diabetes-device-industry" rel="noreferrer noopener">Trump Tariffs Spare Drugmakers But Threaten Diabetes Device Industry</a>
In the first quarter, the company reported: 
<ul>
<li>An adjusted EPS of 64 cents. It beat the consensus of 60 cents and remained within the management <a href="https://www.benzinga.com/general/health-care/25/02/43672055/heart-devices-focused-edwards-lifesciences-confident-in-2025-outlook-analyst-sees-long-term-strength" target="_blank" rel="noreferrer noopener">guidance of 58-64 cents</a>.</li>
<li>Transcatheter Aortic Valve Replacement (TAVR) sales of $1.05 billion. That&#8217;s up 3.8% (+5.4% on a constant currency basis, or <a href="https://www.benzinga.com/pressreleases/25/04/b44964740/edwards-lifesciences-reports-first-quarter-results" target="_blank" rel="noreferrer noopener">6.5% further adjusted)</a>.</li>
<li>Transcatheter Mitral and Tricuspid Therapies (TMTT) first-quarter sales were $115 million, representing growth of 58% year-over-year or more than 60% on a constant currency basis. </li>
<li>In Surgical, first-quarter global sales of $251 million increased 1% over the prior year, or 3% on a constant currency basis.</li>
</ul>
Guidance:&nbsp;Edwards Lifesciences expects second quarter 2025 adjusted EPS of 59-65 cents versus the consensus of 62 cents and revenue of $1.45 billion-$1.53 billion compared to the consensus of $1.46 billion.
The company reaffirmed the fiscal year 2025 adjusted EPS guidance of $2.40-$2.50, compared to the consensus of $2.46, and adjusted operating margins of 27%-28%.
Edwards on Thursday raised its 2025 TMTT sales guidance to $530 to $550 million, from $500 million to $530 million, driven by more favorable foreign exchange and continued business momentum.
The company, TAVR, and Surgical sales growth guidance ranges remain unchanged.
However, on Thursday, the company increased its original total company sales dollar guidance range by $100 million to account for the recent movement in FX rates. Edwards now expects total company sales of $5.7 to $6.1 billion, up from prior guidance of $5.60 billion—$6 billion compared to the consensus of $5.81 billion.
Piper Sandler upgraded Edwards Lifesciences stock, citing a better pathway back to double-digit growth in FY2026.
Analyst Adam C. Maeder writes, &#8220;While shares have traded reasonably well YTD on a relative basis (-5% vs. -8% for S&amp;P 500), EW remains a highly debated name amongst the investment community. We concede our upgrade call could be a bit on the early side.&#8221;
Piper Sandler upgraded the stock from Neutral to Overweight with a price <a target="_blank" href="https://www.benzinga.com/quote/EW/analyst-ratings" rel="noreferrer noopener">target raise from $73 to $80</a>.
&#8220;We also like EW&#8217;s positioning in an uncertain macro environment, namely, the company has little elective procedure exposure, no capex revenue, and a manageable anticipated tariff impact,&#8221; analyst Maeder adds.
Regarding macro/tariffs, William Blair writes that foreign exchange still hurt sales by 1.5% this quarter, but that was about 2% better than expected. The company now expects FX to have no impact on 2025 sales, changing from a previous forecast of a 2.5% drag.
As for tariffs, even though most U.S. supply comes from the company&#8217;s Irvine facility, the 5 cent hit to earnings per share comes from imports out of Singapore, Costa Rica, and, to a lesser extent, Europe.
Baird maintains Edwards Lifesciences with a Neutral, raising the price target from $72 to $75.
Price Action: EW stock is up 6.66% at $75.15 at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44982328/american-airlines-flies-into-uncertainty-q1-revenue-miss-2025-outlook-pulled-but-debt-plan-on-track" target="_blank" rel="noreferrer noopener">American Airlines Flies Into Uncertainty: Q1 Revenue Miss, 2025 Outlook Pulled, But Debt Plan On Track</a></li>
</ul>
Image: Shutterstock

Analyst Color

Large Cap

Upgrades

Health Care

Trading Ideas

Edwards Lifesciences Stock Earns Analyst Upgrade As Growth Outlook Brightens

TFII

TFI International shares are trading higher. The company reported Q1 financial results.

BBDO

BSBR

Shares of banking companies are trading higher amid overall market strength due to March's strong durable goods orders economic data, and President Trump's announcement that he met with China earlier today.

e.l.f. Beauty shares are trading higher. Truist Securities maintained a Buy rating on the stock.

<a href="https://www.bloomberg.com/news/articles/2025-04-24/bessent-sees-us-south-korea-trade-understanding-by-next-week">https://www.bloomberg.com/news/articles/2025-04-24/bessent-sees-us-south-korea-trade-understanding-by-next-week</a>

Politics

Economics

'Bessent Sees US, South Korea Trade 'Understanding' by Next Week'- Bloomberg

Press Releases

Twist Bioscience to Present at 43rd Annual J.P. Morgan Healthcare Conference

Twist Bioscience to Report Fiscal 2025 First Quarter Financial Results on Monday, February 3, 2025

Gene Synthesis Market Size to Surpass USD 9.54 Billion by 2033 | Straits Research

Twist Bioscience Announces Fiscal 2025 First Quarter Financial Results

Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Twist Bioscience to Present at Upcoming Investor Conferences

Twist Bioscience Offers Clonal Genes for Global Academic Researchers at Express Speed for No Extra Cost

Twist Bioscience and Curio Genomics Collaborate to Accelerate and Streamline NGS Adoption in Agrigenomics

Twist Bioscience to Report Fiscal 2025 Second Quarter Financial Results on Monday, May 5, 2025

Twist Bioscience Expands Universal Adapter Portfolio with Launch of High Throughput UDI Adapter System

Comments

Twist Bioscience

뉴스

파트너 / 기고자

벤징가 글로벌